Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOtorhinolaryngology (ENT)Aetna aerosolized sinusitis coverage | OpenPayer
    Ask Trek AI about this page
    CurrentAetnaPolicy 0593

    Aerosolized or Irrigated Anti-infectives for Sinusitis

    Customize your policy alerts

    Sign up for Aetna Policy 0593 alerts

    Get alerted when Policy 0593 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs the use and coverage stance for nasally aerosolized or irrigated anti-infective therapies for sinusitis for Aetna members.

    Policy Summary
    PayerAetna
    PolicyAerosolized or Irrigated Anti-infectives for Sinusitis
    Policy CodePolicy 0593
    Change TypeNo material change
    Effective DateMar 8, 2002
    Last ReviewSep 7, 2023
    Next Review DateJun 27, 2024
    Key ActionDo not authorize nasally aerosolized or irrigated anti-infectives for sinusitis; these uses are considered experimental/investigational and may be denied.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Experimental/Investigational
    coverage stance
    No convincing RCT benefitRCTs outcome
    10 trialsCochrane review
    2002Policy year
    06/27/2024Next review

    Coverage Determinations

    Experimental/Investigational

    Covered when ALL of the following are met:

    Experimental/Investigational determination: Nasally aerosolized or irrigated anti-infectives are considered experimental and investigational for the treatment of sinusitis and other indications due to inadequate published clinical evidence of effectiveness.

    Policy states lack of guideline support and limited data; use outside clearly established indications (e.g., cystic fibrosis or Pneumocystis pneumonia) should be exercised with caution.

    This Clinical Policy Bulletin addresses the use of nasally aerosolized or irrigated anti-infectives for sinusitis. Professional guidance does not support routine use of these therapies for sinusitis, and the policy notes that such administration is considered experimental and investigational for treatment of sinusitis. Established indications for aerosolized antimicrobials — for example, treatment in patients with cystic fibrosis or Pneumocystis pneumonia — exist in other clinical contexts and are distinct from the sinusitis indication described here. Requests to use nasally aerosolized or irrigated anti-infectives for sinusitis fall outside those established indications and are subject to the policy’s investigational determination.

    Randomized, placebo-controlled trials have not demonstrated convincing clinical benefit from adding nebulized or nasally irrigated antibiotics to saline or placebo in sinusitis. A randomized study by Desrosiers et al (2001) in 20 patients with chronic, refractory sinusitis found no clinically significant difference between nebulized tobramycin-saline solution and nebulized saline, leading the authors to conclude that the addition of tobramycin appears to be of minimal benefit.

    A small randomized, double-blind, placebo-controlled crossover pilot study by Videler et al (2008) in 14 patients with recalcitrant chronic rhinosinusitis reported improvement in symptoms in both antibiotic and placebo (saline) arms, with no significant difference between bacitracin/colimycin and placebo. The investigators noted these small placebo-controlled studies consistently point to no effect from adding topical antibiotics and emphasized the need for larger randomized trials to draw definitive conclusions.

    Coding and Billing

    Other CPT codes related to the CPBCPT
    94664Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device.
    99503Home visit for respiratory therapy care (e.g., bronchodilator, oxygen therapy, respiratory assessment, apnea evaluation).
    HCPCS codes not covered for indications listed in the CPBHCPCSNot Covered
    E0574Ultrasonic/electronic aerosol generator with small volume nebulizer.
    E0575Nebulizer, ultrasonic, large volume.
    E0580Nebulizer, durable, glass or autoclavable plastic, bottle type, for use with regulator or flowmeter.
    E0585Nebulizer, with compressor and heater.
    Other HCPCS codes related to the CPBHCPCS
    A7013Filter, disposable, used with aerosol compressor.
    A7014Filter, non-disposable, used with aerosol compressor or ultrasonic generator.
    A7015Aerosol mask, used with DME nebulizer.
    E0572Aerosol compressor, adjustable pressure, light duty for intermittent use.
    ICD-10 codes referenced as not covered for indications listed in the CPBICD-10Not Covered
    J01.00-J01.91Acute sinusitis.
    J32.0-J32.9Chronic sinusitis.

    Provider Responsibilities and Operational Guidance

    Denial Risk

    Experimental/Investigational — denial risk

    Aetna considers nasally aerosolized or irrigated anti-infectives experimental and investigational for the treatment of sinusitis due to inadequate published clinical evidence of effectiveness. Requests to treat sinusitis with these approaches are at risk of denial.

    • Affected diagnoses: ICD-10 J01.00–J01.91 (Acute sinusitis); J32.0–J32.9 (Chronic sinusitis).
    • Related policy: CPB 0065 - Nebulizers.
    Prior Authorization

    Prior authorization — verify with payer

    There are no specific prior authorization instructions provided in the referenced policy text. Providers should verify member-specific benefit coverage and any plan-level prior authorization requirements through the payer's standard authorization channels before initiating treatment.

    Background and Rationale

    Nebulized and nasally irrigated anti-infectives have been proposed to deliver antibiotics or antifungals directly to the sinus mucosa to improve local concentrations and reduce systemic exposure. Proprietary devices and formulations such as the SinuNEB system and AdhesENT formulations are marketed to enhance deposition and medication adherence within the sinus cavities and claim improved effectiveness compared with systemic administration.

    Published clinical evidence for these approaches is limited and consists mainly of uncontrolled case series, retrospective reviews, and small randomized trials. Manufacturer‑reported uncontrolled series suggested subjective improvement in some patients, but prospective randomized trials have not demonstrated consistent benefit. Leading professional guidelines do not recommend a role for nebulized or nasally irrigated antibiotics in routine sinusitis management, and the literature cautions that data are insufficient to support routine use outside clearly established indications (e.g., cystic fibrosis, Pneumocystis).

    Because available studies are small and often nonrandomized, no firm conclusions about safety or effectiveness can be drawn for routine treatment of sinusitis with nebulized or nasally irrigated anti-infectives.

    Definitions and Devices

    SinuNEB / AdhesENT — device and proprietary formulation definition and manufacturer claims
    DeviceSinuNEB — a device marketed by SinusPharmacy that nebulizes antibiotics, antifungals, and other medications for treatment of sinusitis.
    Proprietary formulationAdhesENT — brand name for SinusPharmacy's unique formulations intended to increase medication adherence in the sinus cavities and improve delivery to the disease site.
    Manufacturer claimsManufacturer states nebulized administration to the sinus lining provides more rapid response, greater effectiveness, reduced reinfection, and fewer side effects compared with oral or IV anti-infectives.
    Evidence summaryManufacturer claims are not supported by sufficient published clinical studies; available uncontrolled and retrospective reports exist but lack prospective randomized data.
    Randomized trial findingsA randomized clinical study (Desrosiers et al., 2001) found no clinically significant difference between nebulized tobramycin–saline and nebulized saline, suggesting minimal benefit of added antibiotic.

    Policy Dates and History

    2023-09-07last_review

    Clinical policy last reviewed on 2023-09-07 per document metadata.

    2024-06-27next_review_scheduledLatest

    Next scheduled policy review date is 2024-06-27 per document metadata.

    2002-03-08effective_date

    Policy originally became effective on 2002-03-08.

    Policy Summary
    PayerAetna
    PolicyAerosolized or Irrigated Anti-infectives for Sinusitis
    Policy CodePolicy 0593
    Change TypeNo material change
    Effective DateMar 8, 2002
    Last ReviewSep 7, 2023
    Next Review DateJun 27, 2024
    Key ActionDo not authorize nasally aerosolized or irrigated anti-infectives for sinusitis; these uses are considered experimental/investigational and may be denied.
    SourceLink
    On This Page
    Coverage DeterminationsCoding and BillingProvider Responsibilities and Operational GuidanceBackground and RationaleDefinitions and DevicesPolicy Dates and History
    Step Therapy

    Therapy sequencing — conservative treatments first

    Conservative therapies such as physiologic saline nasal irrigation and intranasal steroids (for CRS with polyposis) are supported by the literature; topical antimicrobials have limited/low-level evidence and should be considered only after standard therapies and culture-directed approaches when clinically appropriate.

    • Physiologic saline irrigation: supportive evidence for symptom relief.
    • Topical antibiotics: low-level evidence; culture-directed therapy preferred.
    Documentation Required

    Evidence limitations — documentation suggestions

    Published studies are limited in size and quality (many uncontrolled, retrospective, or small randomized trials). Detailed clinical documentation should include indication, prior conservative treatments tried, culture results if topical antibiotics are considered, treatment regimen, and outcome measures.

    • Document prior systemic and topical therapies and duration.
    • Include culture-directed organism and sensitivity when topical antibiotics are used.
    • Record objective and patient-reported outcomes and duration of therapy.
    Note

    Provider responsibility — plan-level guidance only

    This policy summary is a plan-level coverage determination. Treating providers are responsible for all medical advice, diagnosis, and treatment decisions. The Clinical Policy Bulletin is informational and does not replace individualized clinical judgment.